Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer by Powles, Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Phase III, Double-Blind, Randomized Trial That Compared
Maintenance Lapatinib Versus Placebo After First-Line
Chemotherapy in Patients With Human Epidermal Growth
Factor Receptor 1/2–Positive Metastatic Bladder Cancer
Thomas Powles, Robert A. Huddart, Tony Elliott, Shah-Jalal Sarker, Charlotte Ackerman, Robert Jones,
Syed Hussain, Simon Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, GrahamMacdonald,
Sundar Santhanam, John A. Frew, Andrew Stockdale, Simon Hughes, Daniel Berney, and Simon Chowdhury
A B S T R A C T
Purpose
To establish whether maintenance lapatinib after ﬁrst-line chemotherapy is beneﬁcial in human
epidermal growth factor receptor (HER) 1/HER2–positivemetastatic urothelial bladder cancer (UBC).
Methods
Patients with metastatic UBC were screened centrally for HER1/HER2 overexpression. Patients
who screened positive for HER1/2 and who did not have progressive disease during chemotherapy
(four to eight cycles) were randomly assigned one to one to lapatinib or placebo after completion of
ﬁrst-line/initial chemotherapy for metastatic disease. The primary end point was progression-free
survival (PFS).
Results
Between 2007 and 2013, 446 patients with UBC were screened, and 232 with HER1- or HER2-
positive disease were randomly assigned. The median PFS for lapatinib and placebo was 4.5 (95%
CI, 2.8 to 5.4) and 5.1 (95% CI, 3.0 to 5.8) months, respectively (hazard ratio, 1.07; 95% CI, 0.81 to
1.43; P = .63). The overall survival for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) and 12.0
(95% CI, 10.5 to 14.9) months, respectively (hazard ratio, 0.96; 95% CI, 0.70 to 1.31; P = .80).
Discontinuation due to adverse events were similar in both arms (6% lapatinib and 5% placebo). The
rate of grade 3 to 4 adverse events for lapatinib and placebo was 8.6% versus 8.1% (P = .82).
Preplanned subset analysis of patients strongly positive for HER1/HER2 (3+ on immunohisto-
chemistry; n = 111), patients positive for only HER1 (n = 102), and patients positive for only HER2
(n = 42) showed no signiﬁcant beneﬁt with lapatinib in terms of PFS and overall survival (P. .05 for
each).
Conclusion
This trial did not ﬁnd signiﬁcant improvements in outcome by the addition of maintenance lapatinib
to standard of care.
J Clin Oncol 35:48-55. © 2016 by American Society of Clinical Oncology
INTRODUCTION
The overall survival (OS) of patients with meta-
static urothelial bladder cancer (UBC), also known
as transitional cell cancer (TCC), is short. Treat-
ment of metastatic disease focuses on platinum-
based combination chemotherapy in the ﬁrst-line
setting.1,2 After chemotherapy is complete, patients
undergo a period of observation. The majority
of these patients experience a relapse and die
as a result of the disease. Further, second-line
chemotherapy at this point remains controversial,
with no clear survival advantage.3
To date, the Food and Drug Administration
has not approved targeted treatments for meta-
static UBC despite a number of molecular targets,
such as the human epidermal growth factor re-
ceptor (HER) family and vascular endothelial
growth factor, that appear attractive preclinically.4-6
Clinical studies that tested these agents in unselected
patients failed to reproduce this in vivo activity.7-9
Three possible reasons account for these results.
First, the combination of chemotherapy and targeted
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therapy in the UBC population, which has multiple comorbid-
ities, is difﬁcult.7,8,10,11 Second, none of the randomized phase III
trials to date have selected patients based on expression of molecular
targets. Finally, UBC has a high frequency ofmutations, therefore the
targeting of only one protein may be inadequate to achieve clinical
beneﬁt.12
To address these issues, the UK Bladder Cancer Clinical
Studies Group embarked on a phase III randomized trial to test
single lapatinib (an HER1 and HER2 tyrosine kinase inhibitor)
against placebo in HER1- or HER2-positive advanced/metastatic
UBC. The drug was tested in the period after completion of
ﬁrst-line chemotherapy for metastatic disease with the primary
aim of delaying progression-free survival (PFS). The goal was to
maintain the response to chemotherapy; hence, the term
maintenance therapy. Placebo was used as the control to allow
for double blinding.
Lapatinib was chosen as the study drug because it tar-
gets HER1 and HER2, both of which have been implicated in
bladder cancer progression.5,6,13,14 Preclinical and phase II
data support its use in selected patients with HER1- or HER2-
positive cancer (on immunohistochemistry [IHC]).15 In ad-
dition, as a single agent, lapatinib appears to be well tolerated,
which is important in this population where comorbidities are
common.
METHODS
Screening Phase
Eligible patients were those with a component of histologically
conﬁrmed advanced/metastatic TCC of the urothelial tract. Details of
the percentage of TCC histology were not collected. Archived parafﬁn-
embedded tissue was used. There was no limit on the age of the sample.
Sites sent the most recent sample for testing when multiple samples
were available from the same patient. Screening occurred during or after
the completion of ﬁrst-line chemotherapy for metastatic disease. Pa-
thology samples were centrally tested for HER1 and HER2. Patients
with positive results were eligible to participate in the trial. Baseline
characteristics, treatment, and outcome data were collected for the
entire screened population to assess prognostic factors. All patients
gave informed consent for this trial, which has appropriate ethical
approval.
HER1 and HER2 Testing
Overexpression of HER1 and HER2 was performed by using IHC
and ﬂuorescent in situ hybridization (FISH). IHC was performed by
using the avidin-biotinylated peroxidase complex staining method
standardized for both antibodies.16 The primary antibody was incubated
for 1 h per the optimized method for each antibody (Novocastra anti-
bodies HER1 [NCL-EGFR] 1:20 and HER2 [NCL-CBE-356] 1:80; Leica
Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom). IHC
scoring was performed independently and blinded by a single pathologist
to allow for rapid turnaround of samples. Independent double biomarker
assessment would have been preferable, but it was not logistically possible
in this study. Expression was scored by staining intensity (0, negative; 1+,
weakly positive; 2+, moderately positive; 3+, strongly positive).17 Only
patients with 2+ or 3+ on IHC for HER1 and/or HER2 were considered to
be have a positive ﬁnding and were eligible for the study.18 FISH was
performed in patients with equivocal positivity (1+ on IHC with both
antibodies), and all had negative results. This method has been used
previously to test HER1 and HER2 status in lapatinib trials and was
deemed the most appropriate at the time of trial inception.15,16
Key Eligibility Criteria
Patients were required to have completed four to eight cycles of
chemotherapy for advanced metastatic UBC. Random assignment needed
to occur between 4 and 10 weeks after the completion of chemotherapy.
Any recognized chemotherapy regimen for metastatic UBC was permitted.
Prior adjuvant or neoadjuvant chemotherapy was not considered ﬁrst-line
chemotherapy. Patients with radiologic progression of disease during che-
motherapy were excluded. Adequate renal, hematologic, and liver function
were required. Patients with a left ventricular ejection fraction (LVEF) below
the normal range were excluded. Patients were required to be at least 18 years
of age and to have resolution of chemotherapy-related toxicity before random
assignment.
Evaluation on Study
Before random assignment, patient history, examination, trial-related
blood tests, and cross-sectional imaging occurred. Adverse events (AEs)
were graded according to the Common Toxicity Criteria for Adverse Events
(version 3). Disease status and LVEF were assessed every 12 weeks. Re-
sponse and progression were assessed by Response Evaluation Criteria in
Solid Tumors (RECIST; version 1.1). No central review occurred. Patients
were discontinued from the study at progression, withdrawal of consent,
unacceptable toxicity, or death.
Treatment Plan
Patients were randomly assigned in a double-blind manner to lapatinib
or placebo (1:1). Stratiﬁcation occurred by prior response to ﬁrst-line
chemotherapy (stable disease versus partial response/complete response)
and Eastern Cooperative Oncology Group performance status. Lapatinib
was administered continuously at 1,500 mg once daily (six 250-mg
tablets). In the placebo group six visually identical tablets were ad-
ministered instead. Dose reductions to ﬁve (lapatinib = 1,250 mg) or four
(lapatinib = 1,000 mg) tablets could occur based on AEs outlined in the
protocol (Data Supplement).
End Points and Statistical Considerations
The primary end point was PFS from the time of random assignment
to progression or death. All randomly assigned patients were included in
the analysis (Fig 1). This design was intention to treat. Screening for HER1
and HER2 status occurred before study entry (screening population).
Secondary end points were OS; response rates; AEs; and outcome of subsets,
which depended on biomarker status (HER1 or HER2 positive alone or
HER1 and HER2 3+ IHC).
The phase III study required approximately 221 patients for 196
events on the basis of a single-sided design with alpha = .025 to detect
a 60% longer median PFS (hazard ratio [HR], 0.62) in the treatment group
with 90% power. The duration of this PFS was assumed to be 6 months,
although there was a lack of previous data to guide this estimation.
The trial followed a phase III continuous design with interim analyses.
An independent data monitoring committee assessed efﬁcacy and toxicity
data at a prespeciﬁed number of events (15, 31, 49, 98, and 147) against
efﬁcacy (futility) boundaries derived on the basis of the alpha spending
function approach. The trial did not halt for these assessments, and the trial
team remained blinded to the study results until the ﬁnal analysis.
PFS andOSwere compared between study arms by using the log-rank
test stratiﬁed by the baseline stratiﬁcation factors, and corresponding two-
sided 95% CIs were presented to align with the one-sided 2.5% upper-
tailed test. Signiﬁcant factors in univariable Cox proportional hazards
regression analysis for OS were included in a multivariable Cox model to
identify signiﬁcant prognostic variables.
Prognostic Value of HER1 and HER2 in the Screened
Population
Outcomes from the entire screening population were assessed to de-
termine the prognostic value of HER1 orHER2 and to construct a prognostic
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index. The baseline time point for this exploratory analysis of the screening
population was the date of completion of chemotherapy. OS was deﬁned as
the time from completion of chemotherapy to death or most recent follow-
up. To construct the prognostic index, signiﬁcant factors on multivariable
analysis were dichotomized and added together. The prognostic index
further categorized patients as low risk, medium risk, or high risk based
on risk factor presence.
RESULTS
Screening Population
Between 2007 and 2013, 446 patients were screened for
HER1 and HER2 status (Table 1). Overall, 329 (74%) patients were
male, and the median age was 71 years (interquartile range, 64 to
77 years; Table 1). The median number of chemotherapy cycles was
six (interquartile range, four to six cycles), 61% received cisplatin-
based chemotherapy, and 48% had visceral metastasis. Subsequently,
133 (30%) patients received second-line chemotherapy.
The median duration from the time tissue was taken for
diagnosis to screening consent was 5 months (Appendix Fig A1,
online only). Archived tissue was histologically T1 in 11%, T2 to
T3 in 64%, T4 in 22%, and from nodal/metastatic sites in 3%.
HER1 and HER2 positivity did not change with increasing Tstage
(data not shown). Fifteen percent of screened patients were negative
for HER1 and 2, whereas 39%, 13%, and 33% were positive for
HER1 only, HER2 only, and HER1 and HER2, respectively. No
signiﬁcant difference was found in OS in terms of HER status in the
screened population (P = .35; Appendix Fig A2, online only), which
suggests that it is not a prognostic factor. The most common
reasons for ineligibility for random assignment were disease
progression (n = 52 [24%]), patient choice (n = 19 [8%]), and
reduced LVEF (n = 41 [19%]; Fig 1).
Characteristics and Outcomes of the Randomly
Assigned Population
No signiﬁcant differences in characteristics in the screened
or randomly assigned population were found, except that the
randomly assignment population included only patients positive
for HER1/HER2 and excluded those with progression of disease
(Table 1). Two hundred thirty-two patients were assigned to
lapatinib (n = 116) or placebo (n = 116). The PFS for lapatinib and
placebo was 4.5 (95% CI, 2.8 to 5.4) months with 99 events and 5.1
(95% CI, 3.0 to 5.8) months with 102 events, respectively (HR,
1.07; 95% CI, 0.81 to 1.43; P = .63). The OS for lapatinib and
placebo was 12.6 (95% CI, 9.0 to 16.2) months with 80 deaths and
12.0 (95% CI, 10.5 to 14.9) months with 82 deaths, respectively
Lost to follow-up
Discontinued intervention
Progression
Adverse events
Death
Patient choice
Other
(n = 0)
(n = 83)
(n = 5)
(n = 5)
(n = 5)
(n = 18)
Analyzed
(n = 116)
Assigned to placebo
(n = 116)
Analyzed
(n = 116)
Screened
(N = 446)
Randomly assigned
(n = 232)
Enrollment
Lost to follow-up
Discontinued intervention
Progression
Adverse events
Death
Patient choice
Other
(n = 0)
(n = 82)
(n = 7)
(n = 3)
(n = 7)
(n = 17)
Analysis
Follow-up
Assigned to lapatinib
(n = 116)
Allocation
Excluded
Disease progression
Declined to participate
HER1/HER2 negative
Reduced LVEF
Other reasons
Unknown
(n = 52)
(n = 19)
(n = 42)
(n = 41)
(n = 37)
(n = 23)
(n = 214)*
Fig 1. CONSORT diagram. Overview of
screened and randomly assigned patients.
*Only one reason for exclusion was available
on the case report forms. Some patients
possibly had more than one reason for ex-
clusion. HER, human epidermal growth factor
receptor; LVEF, left ventricular ejection factor.
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(HR, 0.96; 95% CI, 0.70 to 1.31; P = .80; Figs 2A and 2B). CIs are
wide because of the modest size of the trial. The best response rate
for lapatinib and placebo were 14% versus 8% (P = .14).
Predeﬁned subset analysis of patients positive for HER1/HER2
3+ on IHC (n = 111 [48%]), those positive for HER1 only (n = 102
[44%]), and those positive for HER2 only (n = 42 [18%]) showed
no signiﬁcant beneﬁt in PFS (HRs, 0.90 [95%CI, 0.59 to 1.36] with
101 events, 0.98 [95% CI, 0.72 to 1.35] with 164 events, and 1.27
[95% CI, 0.87 to 1.85] with 116 events, respectively; P . .05 for
each) or OS (HRs, 0.77 [95% CI, 0.48 to 1.24] with 81 deaths, 0.90
[95% CI, 0.63 to 1.28] with 130 deaths, and 1.06 [95% CI, 0.69 to
1.62] with 90 deaths, respectively; P . .05 for each) for lapatinib.
Subgroup forest plot analysis also did not show a subgroup of patients
who beneﬁted from therapy (Appendix Fig A3, online only).
Dose Reduction and AE Profile
Lapatinib dose was reduced in 17 (7%) patients. Discontinuation
due to AEs was similar in both arms (6% lapatinib and 5% placebo).
No signiﬁcant difference was found in the frequency of AEs, which
occurred in. 10% of patients (Table 2). The rate of grade 3 to 4 AEs
for lapatinib and placebo was 8.6% versus 8.1% (P = .82).
Prognosis of Patients at the Time of Completion of
Chemotherapy
The median OS for the screened population (n = 446) from
the time of completion of chemotherapy was 11.8 (95% CI, 10.0
to 12.9) months. Univariable analysis for survival was performed
by using the screened population at the time of completion of
chemotherapy (Table 3). Signiﬁcant variables were included in
the multivariable analysis, and results showed that poor per-
formance status (HR, 1.53; 95% CI, 1.28 to 1.84; P , .001) and
progression with chemotherapy (HR, 4.2; 95% CI, 2.63 to 6.72;
P , .001) were associated with a poor OS. Visceral metastasis
(HR, 1.32; 95% CI, 1.01 to 1.71; P = .04) was also signiﬁcant. A
prognostic index that incorporated these factors was generated.
Figure 3 shows the survival of the three prognostic groups within
this prognostic index. The 1-year OS for low-, medium-, and
high-risk patients was 61.2% (95% CI, 52.4% to 68.9%), 49.1%
Table 1. Patient Demographics and Clinical Characteristics
Characteristic
Screened but Not Randomly Assigned,
No. (%)
Randomly Assigned (n = 232),
No. (%)
Total, No. (%)Lapatinib Placebo
No. of patients 214 116 116 445
Sex
Female 57 (26.6) 28 (24.1) 32 (27.6) 117 (26.2)
Male 157 (73.4) 88 (75.9) 84 (72.4) 329 (73.8)
Median age (IQR), years 70.4 (64.7-77.2) 70.7 (63.9-77.2) 71.1 (63.8-76.3) 70.7 (64.2-77.1)
Performance status
0 30 (22.6) 53 (45.7) 52 (44.8) 125 (35.2)
1 79 (59.4) 52 (44.8) 51 (44.0) 187 (52.7)
. 1 24 (18.1) 11 (9.5) 13 (11.5) 43 (12.1)
Response to previous chemotherapy
CR or PR 92 (51.1) 80 (69.0) 78 (67.2) 250 (60.7)
SD 36 (20.0) 36 (31.0) 38 (32.8) 110 (26.7)
PD 52 (28.9) 0 (0.0) 0 (0.0) 52 (12.6)
Tumor grade
1 or 2 16 (9.3) 4 (4.0) 4 (4.0) 24 (6.4)
3 or 4 156 (90.7) 98 (96.0) 98 (96.1) 352 (93.7)
Visceral metastasis
Yes 77 (46.1) 60 (53.6) 47 (43.1) 214 (48.0)
No 90 (53.9) 52 (46.4) 62 (56.9) 232 (52.0)
HER status
HER1 positive 73 (34.1) 53 (45.7) 49 (42.2) 175 (39.2)
HER2 positive 18 (8.4) 21 (18.1) 21 (18.1) 60 (13.5)
Both positive 57 (26.6) 42 (36.2) 46 (39.7) 145 (32.5)
HER negative 66 (30.8) 0 (0.0) 0 (0.0) 66 (14.8)
Previous cisplatin-based chemotherapy
Yes 114 (57.3) 71 (64.0) 73 (65.2) 258 (61.4)
No 85 (42.7) 40 (36.0) 39 (34.8) 164 (38.9)
Hemoglobin level
Normal 17 (9.2) 31 (28.4) 26 (22.4) 74 (18.1)
Low 168 (90.8) 78 (71.6) 90 (77.6) 336 (81.9)
Albumin level
Normal 157 (88.7) 108 (99.1) 111 (97.4) 376 (94.0)
Low 20 (11.3) 1 (0.9) 3 (2.6) 24 (6.0)
Creatinine level
Normal 77 (41.9) 49 (45.0) 36 (31.6) 162 (39.8)
High 107 (58.1) 60 (55.0) 78 (68.4) 245 (60.2)
Abbreviations: CR, complete response; HER, human epidermal growth factor receptor; IQR, interquartile range; PD, progression of disease; PR, partial response; SD,
stable disease.
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(95%CI, 40.7% to 57.1%), and 21.9% (95%CI, 12.7% to 32.6%),
respectively.
DISCUSSION
Maintenance lapatinib was not associated with clinical beneﬁt in
patients with HER1- and HER2-positive bladder cancer tumors as
measured by our biomarker assay. Further analysis of subsets of
patients positive for HER1 or HER2 did not show signiﬁcant
beneﬁt associated with the drug, even in those tumors that
expressed the highest level of the biomarker (3+ on IHC15), which
reinforces the lack of beneﬁt. To our knowledge, this study is the
ﬁrst randomized phase III therapy trial in metastatic UBC to
enrich for biomarkers and to use a maintenance design. The
phase II results with lapatinib were worthy of further in-
vestigation in biomarker-positive patients with UBC previously
treated with chemotherapy,15 which justiﬁed the current study.
However, our strategy was unsuccessful for a number of possible
reasons. First, although the targeting of HER proteins in iso-
lation in breast cancer has been successful, they may not be
a target associated with clinical beneﬁt in UBC.8,19 Recent
studies that investigated trastuzumab (HER2 antibody) with
chemotherapy in UBC with HER2 gene ampliﬁcation also do
not support this theory.19 Different rates of biomarker positiv-
ity are seen with different methodologies, which highlights the
B
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Fig 2. Comparison of outcomes for the randomly
assigned population by Kaplan-Meier method. (A)
Progression-free survival (the primary end point). (B)
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uncertainty around biomarker selection in this setting. Second,
archived parafﬁn-embedded tissue was used to measure bio-
marker expression, which may not have been representative of
current biomarker status. In addition, cancer tissue consisted
largely of tissue from the bladder which may not be representative
of metastatic disease. Third, the method of biomarker assessment
(IHC and FISH analyses), which has been used successfully in breast
cancer,20 may not be an effective approach in UBC. A spectrum of
various IHC methodologies have been used to assess HER ex-
pression across different cancers.21 Our biomarker selection may be
partly responsible for the results. Gene expression or ampliﬁcation
methodologies may be preferable in UBC. Fourth, the trial had an
ambitious design by testing for a large clinical beneﬁt in an enriched
population. The CIs, therefore, are wide, which means that modest,
but clinically meaningful differences were not detectable. Finally,
although lapatinib has activity in other HER-positive cancers, it may
not have activity in UBC, and other methods of targeting the HER
family may be preferable. A recent phase II study in UBC with
afatinib (an ERBB family inhibitor) showed promising activity.22
Therefore, activity that occurs with a different drug or biomarker is
conceivable.
The maintenance trial design in this setting has not been
used in previous randomized phase III studies in UBC, although
other smaller studies that investigated sunitinib and vinﬂunine
have been reported.9,23 The study with sunitinib showed short PFS
and OS after chemotherapy, whereas the results with vinﬂunine
suggested possible clinical activity. A new generation of immune
therapy studies currently uses this trial design (NCT02500121).
Results from the screened population show that HER1 or
HER2 status is not prognostic (Appendix Fig A2). This is the most
robust analysis of this issue to our knowledge, which sheds light on
previously contradictory data and increases our understanding of
this complex area complicated by the various methodologies used
to measure HER1 and HER2.13,14,16,18,24,25 Different methods of
molecular analysis are possibly responsible for these contradictory
results. Further work is required to determine whether HER1 or
HER2 plays a role in UBC.13,14 This trial offered the opportunity to
Table 2. Number of Patients by Treatment Arm, Adverse Event Type, and
Grade
Adverse Event
Lapatinib (n = 97), No.
(%)
Placebo (n = 99), No.
(%)
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
Anorexia 12 (12.4) 0 (0.0) 7 (7.1) 0 (0.0)
Constipation 14 (14.4) 2 (2.1) 17 (17.2) 1 (1.0)
Cough 8 (8.2) 0 (0.0) 9 (9.1) 1 (1.0)
Diarrhea 59 (60.8) 6 (6.2) 22 (22.2) 1 (1.0)
Fatigue 34 (35.1) 4 (4.1) 41 (41.4) 1 (1.0)
Infection 26 (26.8) 5 (5.2) 14 (14.1) 4 (4.0)
Itch 12 (12.4) 0 (0.0) 11 (11.1) 1 (1.0)
Nausea 22 (22.7) 1 (1.0) 19 (19.2) 1 (1.0)
Neuropathy 7 (7.2) 0 (0.0) 13 (13.1) 1 (1.0)
Pain 37 (38.1) 10 (10.3) 41 (41.4) 6 (6.1)
Rash 43 (44.3) 2 (2.1) 21 (21.2) 0 (0.0)
Shortness of breath 12 (12.4) 0 (0.0) 7 (7.1) 3 (3.0)
Vomiting 15 (15.5) 3 (3.1) 15 (15.2) 1 (1.0)
NOTE. The most common adverse events were graded according to the
Common Terminology Criteria for Adverse Events (version 3). Data were in-
adequately recorded or missing for 36 patients, equally balanced in both arms.
Table 3. Univariable Analysis for Prognostic Factors at the Time of Completion of Chemotherapy
PFS OS
No. of Patients Events HR 95% CI P No. of Patients Events HR 95% CI P
Age 353 313 0.99 0.98 to 1.01 .31 393 313 1.00 0.99 to 1.01 .87
Sex
Female 101 92 1 — — 106 93 1 — —
Male 252 221 0.82 0.64 to 1.05 .12 287 220 0.82 0.65 to 1.05 .12
ECOG PS 310 274 1.25 1.06 to 1.48 .01 336 261 1.55 1.32 to 1.83 , .001
HER status
HER negative 44 41 1 — — 47 43 1
HER1 positive 141 121 1.21 0.85 to 1.72 .30 158 125 1.07 0.75 to 1.51 .72
HER2 positive 53 48 1.25 0.82 to 1.90 .29 58 48 0.90 0.59 to 1.36 .62
Both positive 115 103 1.00 0.70 to 1.44 .99 130 97 0.84 0.59 to 1.21 .36
Visceral metastasis
No 176 151 1 — — 184 137 1 — —
Yes 146 133 1.27 1.01 to 1.61 .044 169 140 1.44 1.14 to 1.83 .002
Response to previous chemotherapy
CR or PR 235 209 1 — — 230 184 1 — —
SD 110 98 1.03 0.81 to 1.31 .83 109 78 0.94 0.72 to 1.23 .67
PD — — — — — 47 46 3.06 2.20 to 4.26 , .001
Tumor grade
1 and 2 16 13 1 — — 21 15 1 — —
3 and 4 290 257 1.10 0.63 to 1.92 .75 318 253 1.31 0.78 to 2.20 .32
Previous cisplatin-based chemotherapy
No 137 126 1 — — 148 122 1 — —
Yes 206 177 0.81 0.65 to 1.02 .07 235 183 0.81 0.64 to 1.02 .07
Hemoglobin level 337 298 1.00 0.99 to 1.01 .75 374 296 1.00 0.99 to 1.01 .64
Albumin level 331 293 0.97 0.94 to 0.99 .01 366 289 0.92 0.89 to 0.94 , .001
Creatinine level 334 295 0.998 0.996 to 1.001 .153 371 293 0.998 0.996 to 1.001 .158
Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; HER, human epidermal growth factor receptor; HR, hazard ratio; OS, overall
survival; PD, progression of disease; PFS, progression-free survival; PR, partial response; PS, performance status; SD, stable disease.
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explore the importance of gene expression in unselected patients,
but we focused predominately on protein expression. Future re-
search in this area would be helpful.
The trial design allowed us to study the characteristics and
outcomes of unselected patients after the completion of chemo-
therapy, which has not been reported previously. More than one
half (61%) of the patients received cisplatin, and a high proportion
(48%) had visceral metastasis, which gives some insight into the
current population of patients who receive chemotherapy. Survival
was short after the completion of chemotherapy (, 1 year) in both
the randomly assigned and screened populations, which underscores
the poor outcome for patients with metastatic UBC, particularly
those not eligible for cisplatin chemotherapy.1 Only 30% of patients
received second-line chemotherapy (29 in the lapatinib arm and 34
in the placebo arm; P = .49), which may have contributed to this
ﬁnding. Together, these results show that patients with UBC have
a poor outcome, even if they initially gained clinical beneﬁt from
chemotherapy.25 Whether the patients in this study had a less-than-
expected good outcome remains largely unknown because of the
paucity of comparative data in this setting.
Prognostic factors were also assessed in this population. Pre-
vious studies of prognostic factors focused on clinical parameters
before the start of ﬁrst-line therapy.26 The current trial design allowed
us to analyze prognostic factors at the time of completion of che-
motherapy. Results showed that radiologic progression on chemo-
therapy, visceral metastasis, and poor performance status were
associated with a poor outcome in multivariable analysis. A prognostic
model that consisted of these factors was constructed and discrimi-
nated patients into three groups. Although further validation is re-
quired, this information is novel and helpful to patients and their
caregivers.
The trial design was pragmatic and allowed for a varying
number of chemotherapy cycles and regimens. Previous peri-
operative therapy was not an exclusion criterion, and the pro-
portion of patients who received this was not recorded. In addition,
patients could be randomly assigned up to 10 weeks after
chemotherapy. Although this makes the study applicable to a broad
spectrum of patients, it may introduce bias. Results show that the
median number of chemotherapy cycles and the use of cisplatin
were similar in both random assignment groups, which alleviates
some of these concerns. However, differences in the quality of
responses between cisplatin and carboplatin are a concern. Indeed,
a signiﬁcant proportion of patients who received placebo had
continued response, which suggests ongoing activity of che-
motherapy beyond the last dose administered.
Despite these shortcomings, this study shows that lapatinib
does not signiﬁcantly improve outcomes in this subset of patients
with UBC. Further exploration with different agents and different
biomarkers continue. A more detailed understanding of the role
of HER1 and HER2 in UBC should be pursued in future trials.
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Fig A1. Time from tissue collection (archived formalin-ﬁxed parafﬁn-embedded tissue) to screening.
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Fig A2. Kaplan-Meier overall survival curve by human epidermal growth factor receptor (HER) status from completion of chemotherapy.
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